Motixafortide
Also known as: Aphexda, BL-8040, BSN324, Motixafortide, POL6326
Source Motixafortide at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Motixafortide (formerly BL‑8040) is a synthetic cyclic peptide CXCR4 antagonist under investigation for stem cell mobilization in autologous transplantation and as an adjunct to cancer immunotherapy.
Mechanism of Action
Competitive antagonism of the CXCR4 receptor, blocking stromal cell-derived factor‑1 (SDF‑1) binding, leading to hematopoietic stem cell mobilization and modulation of tumor microenvironment.
Routes of Administration
Goals & Uses
- Enhancement of anti‑tumor immunityOncologyModerate
- Hematopoietic stem cell mobilizationHematologyHigh
- Pancreatic cancer treatmentOncologyLow
- Reduction of apheresis sessionsProcedural EfficiencyHigh
- Acute Myeloid Leukemia (AML) TreatmentHematology/OncologyLow
Contraindications
- PregnancyPopulationModeratePotential fetal risk or insufficient safety data
- Known hypersensitivity to motixafortide or excipientsAllergyHigh
- Active systemic infectionInfectiousModerate
- Hypersensitivity to motixafortide or any excipientAllergyHigh
Adverse Effects
- Injection site reactionsLocalCommon
- Hypersensitivity/anaphylaxisImmunologicalUncommon
- HypotensionCardiovascularRareLow blood pressure
- Nausea/vomitingGastrointestinalCommon
- FlushingVascularCommonWarmth and redness of the skin
- Orthostatic hypotensionCardiovascularUncommon
- NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit
- Transient leukocytosisHematologicalUncommon
- Injection site erythemaLocalCommonRedness at the injection site
- DizzinessNeurologicCommonFeeling faint, lightheaded, or unsteady
Drug Interactions
- Granulocyte‑colony stimulating factor (G‑CSF)Moderate
- Filgrastim (G-CSF)Low
- Other CXCR4 antagonistsHigh
- PlerixaforModerate
Population Constraints
- PregnancyReproductive SafetyRelative
- Severe renal impairmentOrgan ImpairmentRelative
- Pediatric patientsAgeRelative
- LactationReproductiveRelative
- Elderly (>75 years)GeriatricRelative
Regulatory Status
- European UnionInvestigationalUnder EMA review for stem‑cell mobilization.
- United StatesInvestigationalPhase 3 trials ongoing; not FDA‑approved.
- United KingdomInvestigationalClinical trials authorized; not MHRA‑approved.
FDA approved August 2023 under the brand name Aphexda in combination with filgrastim for HSC mobilization in multiple myeloma patients. Orphan Drug Designation granted. Not yet approved in EU or UK as of 2024.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Motixafortide?
Motixafortide (formerly BL‑8040) is a synthetic cyclic peptide CXCR4 antagonist under investigation for stem cell mobilization in autologous transplantation and as an adjunct to cancer immunotherapy.
What is Motixafortide used for?
Motixafortide is educationally associated with: Enhancement of anti‑tumor immunity, Hematopoietic stem cell mobilization, Pancreatic cancer treatment, Reduction of apheresis sessions, Acute Myeloid Leukemia (AML) Treatment. Educational only — not medical advice.
How is Motixafortide administered?
Recorded routes of administration: Intravenous, Subcutaneous.
What are the potential side effects of Motixafortide?
Reported adverse effects include: Injection site reactions, Hypersensitivity/anaphylaxis, Hypotension, Nausea/vomiting, Flushing, Orthostatic hypotension, Nausea, Transient leukocytosis, Injection site erythema, Dizziness. This list is not exhaustive — consult a qualified clinician.
Who should avoid Motixafortide?
Recorded contraindications: Pregnancy, Known hypersensitivity to motixafortide or excipients, Active systemic infection, Hypersensitivity to motixafortide or any excipient. Consult a qualified clinician before use.